[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100064673":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":16,"centralContacts":7,"locations":7,"responsibleParty":20,"collaborators":7,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":7,"eligibilityCriteria":28,"healthyVolunteers":29,"sex":30,"minAge":31,"maxAge":32,"enrollmentInfo":33,"targetDuration":7,"studyType":36,"phases":37,"briefSummary":39,"conditions":40,"keywords":7,"overallStatus":45,"whyStopped":7,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":7},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",null,[9,14],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":12},"BIOLOGICAL","measles, mumps, and rubella virus vaccine live",[13],"V205C",{"type":10,"name":15,"description":7,"armGroupLabels":7,"otherNames":7},"Comparator: Measles, Mumps, and Rubella Virus Vaccine Live",[17],{"name":18,"affiliation":5,"role":19},"Medical Monitor","STUDY_DIRECTOR",{"type":21,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100064673","phase-2-safety-tolerability-and-immunogenicity-of-an-investigational-vaccine-with-recombinant-human-albumin-rha-in-children-12-to-18-months-of-age-v205c-009completed-100064673",false,"NCT00092404","Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)","A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age","Inclusion Criteria:\n\n* Healthy children 12 to 18 months of age\n\nExclusion Criteria:\n\n* History or prior exposure to measles, mumps, or rubella\n* History of allergic reactions to any component of the vaccines as evaluated by the study doctor",true,"ALL","12 Months","18 Months",{"count":34,"type":35},1210,"ACTUAL","INTERVENTIONAL",[38],"PHASE2","The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.",[41,42,43,44],"Measles","Mumps","Rubella","Varicella","COMPLETED","2017-03-14",{"date":48,"type":35},"2017-03-15",{"date":50,"type":7},"2001-12",{"date":52,"type":35},"2005-06",{"name":5,"class":6}]